About 7,990,000 results
Open links in new tab
IASLC: Ivonescimab vs Pembrolizumab as First-Line Treatment in …
Promising Anti-Tumor Activity and Safety of Ivonescimab in …
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in …
Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated …
Summit therapy beat Merck blockbuster Keytruda in late-stage …
Akeso’s Ivonescimab plus Chemo in First-Line Triple ... - BioSpace
Ivonescimab outperforms pembrolizumab in study for first-line …
Ivonescimab Tops Pembro in Advanced PD-L1-Positive NSCLC
Ivonescimab Monotherapy Decisively Beats Pembrolizumab …
Akeso Published First-Ever Efficacy Data for PD-1/VEGF ... - BioSpace